BioVie Receives Notice Of Allowance For U.S. Patent Application Covering Novel Liquid Formulation Of Terlipressin
Portfolio Pulse from Benzinga Newsdesk
BioVie Inc. has received a Notice of Allowance for a U.S. patent application covering a novel liquid formulation of terlipressin, which is stable at room temperature for up to 24 months. This formulation is intended for treating patients with cirrhosis and ascites, offering a more patient-centric treatment option.
October 01, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioVie Inc. has received a Notice of Allowance for a U.S. patent on a novel liquid formulation of terlipressin, which is stable at room temperature for 24 months. This development could enhance treatment options for cirrhosis and ascites, potentially increasing BioVie's market presence.
The Notice of Allowance for the U.S. patent on BioVie's terlipressin formulation is a significant milestone, as it secures intellectual property rights in a major market. The formulation's stability and potential for home-care use could make it a preferred treatment option, enhancing BioVie's competitive position and potentially driving stock price upward.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100